Literature DB >> 16403996

Treatment of agitation following traumatic brain injury: a review of the literature.

Matthew Levy1, Andrea Berson, Theresa Cook, Natasha Bollegala, Eva Seto, Shannon Tursanski, Jennifer Kim, Sanjeev Sockalingam, Anshu Rajput, Nupura Krishnadev, Chris Feng, Shree Bhalerao.   

Abstract

Agitation, restlessness, and aggression are frequent neurobehavioural sequelae in the early stages of recovery from traumatic brain injury (TBI). These behavioural symptoms disrupt patient care and impede rehabilitation efforts. We review the current literature (1985 onwards) examining the pharmacological management of post-TBI agitation in both acute and post-acute conditions. This article will assess the evidence for the use of selected alkylphenols, benzodiazepines, estrogens, antiandrogens, neuroleptics/antipsychotics, antidepressants, anti-Parkinsonian agents, antipsychotics, anticonvulsants, lithium carbonate, buspirone, beta-blockers, and psychostimulants in agitated TBI survivors. Review of the literature suggests that there is limited evidence to accurately guide clinicians in the management of this patient population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16403996

Source DB:  PubMed          Journal:  NeuroRehabilitation        ISSN: 1053-8135            Impact factor:   2.138


  13 in total

1.  Differential effects of single versus multiple administrations of haloperidol and risperidone on functional outcome after experimental brain trauma.

Authors:  Anthony E Kline; Jaime L Massucci; Roos D Zafonte; C Edward Dixon; Judith R DeFeo; Emily H Rogers
Journal:  Crit Care Med       Date:  2007-03       Impact factor: 7.598

2.  Spontaneous recovery after controlled cortical impact injury is not impeded by intermittent administration of the antipsychotic drug risperidone.

Authors:  Lauren J Carlson; Gina C Bao; Sonya Besagar; Jacob B Leary; Hannah L Radabaugh; Corina O Bondi; Anthony E Kline
Journal:  Neurosci Lett       Date:  2018-06-06       Impact factor: 3.046

Review 3.  Neurocritical care nursing research priorities.

Authors:  D M Olson; M M McNett; S Livesay; P D Le Roux; J I Suarez; C Bautista
Journal:  Neurocrit Care       Date:  2012-02       Impact factor: 3.210

4.  Comprehensive brain injury agitation management in the critical care setting: Preliminary results on a multidisciplinary neurobehavioral approach.

Authors:  Eugene J Rankin; Danny Jazarevic; Rona Altaras
Journal:  J Intensive Care Soc       Date:  2019-05-13

5.  Evaluating the use of dexmedetomidine in neurocritical care patients.

Authors:  Tina M Grof; Kathleen A Bledsoe
Journal:  Neurocrit Care       Date:  2010-06       Impact factor: 3.210

Review 6.  Brain serotonin receptors and transporters: initiation vs. termination of escalated aggression.

Authors:  Aki Takahashi; Isabel M Quadros; Rosa M M de Almeida; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2010-09-03       Impact factor: 4.530

7.  Chronic administration of antipsychotics impede behavioral recovery after experimental traumatic brain injury.

Authors:  Anthony E Kline; Ann N Hoffman; Jeffrey P Cheng; Ross D Zafonte; Jaime L Massucci
Journal:  Neurosci Lett       Date:  2008-10-25       Impact factor: 3.046

8.  Relative to Typical Antipsychotic Drugs, Aripiprazole Is a Safer Alternative for Alleviating Behavioral Disturbances After Experimental Brain Trauma.

Authors:  Thomas I Phelps; Corina O Bondi; Vincent V Mattiola; Anthony E Kline
Journal:  Neurorehabil Neural Repair       Date:  2016-05-24       Impact factor: 3.919

Review 9.  Interrelation between Neuroendocrine Disturbances and Medical Complications Encountered during Rehabilitation after TBI.

Authors:  Caroline I E Renner
Journal:  J Clin Med       Date:  2015-09-22       Impact factor: 4.241

10.  Use of olanzapine to treat agitation in traumatic brain injury: study protocol for a randomised controlled trial.

Authors:  Ruby K Phyland; Adam McKay; John Olver; Mark Walterfang; Malcolm Hopwood; Amelia J Hicks; Duncan Mortimer; Jennie L Ponsford
Journal:  Trials       Date:  2020-07-20       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.